Candriam S.C.A. Trims Stake in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Candriam S.C.A. reduced its stake in Regeneron Pharmaceuticals by 17.8%, owning 214,941 shares worth approximately $136.32 million, making up 0.9% of its portfolio.
• Regeneron's stock received a series of analyst upgrades, with BMO Capital Markets raising the target price from $600 to $640 and multiple other firms giving the stock a consensus rating of "Moderate Buy."
• The company recently declared a quarterly dividend of $0.88 per share, with a total annualized yield of 0.6% and a low payout ratio of 8.87%.

Candriam S.C.A. lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 17.8% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 214,941 shares of the biopharmaceutical company's stock after selling 46,557 shares during the quarter. Regeneron Pharmaceuticals accounts for 0.9% of Candriam S.C.A.'s holdings, making the stock its 24th biggest holding. Candriam S.C.A. owned approximately 0.20% of Regeneron Pharmaceuticals worth $136,322,000 as of its most recent filing with the SEC.

Other large investors have also recently modified their holdings of the company. Pinney & Scofield Inc. bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. grew its position in Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 31 shares during the last quarter. Costello Asset Management INC bought a new position in Regeneron Pharmaceuticals in the 1st quarter valued at $27,000. Tompkins Financial Corp bought a new position in Regeneron Pharmaceuticals in the 1st quarter valued at $32,000. Finally, Curat Global LLC bought a new position in Regeneron Pharmaceuticals in the 1st quarter valued at $32,000. Institutional investors own 83.31% of the company's stock.

Analyst Ratings Changes

Several brokerages have commented on REGN. BMO Capital Markets upped their price objective on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a research report on Monday, August 4th. Argus downgraded Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. Wells Fargo & Company downgraded Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price target on the stock. in a research report on Friday, August 1st. Redburn Atlantic upgraded Regeneron Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, August 14th. Finally, Morgan Stanley restated an "overweight" rating and set a $761.00 price objective (up from $754.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $829.65.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock traded down $8.68 during mid-day trading on Friday, reaching $589.48. The stock had a trading volume of 1,438,624 shares, compared to its average volume of 992,485. The firm has a market cap of $62.48 billion, a price-to-earnings ratio of 14.86, a PEG ratio of 1.99 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20. The business's fifty day moving average is $550.48 and its 200-day moving average is $592.20. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. The firm had revenue of $3,675,600 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.Regeneron Pharmaceuticals's revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period last year, the company earned $11.56 earnings per share. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.